Lexicon Pharmaceuticals to Host 2024 Investor Day
18 Abril 2024 - 7:00AM
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced
that senior company executives will be joined by leading physicians
at the Lexicon 2024 Investor Day on April 22, 2024. The event will
be held in New York City from 9:00 a.m. to 12:00 p.m. ET.
Business and scientific updates will be presented by Lonnel
Coats, Lexicon’s chief executive officer; Jeff Wade, Lexicon’s
president and chief financial officer; Alan Main, Ph.D., Lexicon’s
executive vice president, innovation and chemical sciences; Tom
Garner, Lexicon’s senior vice president and chief commercial
officer; and Craig Granowitz, M.D., Ph.D., Lexicon’s senior vice
president and chief medical officer.
The corporate presentations and panel discussion with renowned
medical leaders will highlight Lexicon’s strategy and efforts to
address major areas of need in:
- Heart Failure
- Diabetic Peripheral Neuropathic Pain
- Hypertrophic Cardiomyopathy
- Type 1 Diabetes
- Obesity and Weight Management
The simultaneous webcast will be available in the “Events”
section of the Lexicon website at www.lexpharma.com/events,
and a recording of the webcast will be available for two weeks
following the original on-demand date.
About Lexicon Pharmaceuticals
Lexicon is a biopharmaceutical company with a mission of
pioneering medicines that transform patients’ lives. Through its
Genome5000™ program, Lexicon scientists studied the role and
function of nearly 5,000 genes and identified more than 100 protein
targets with significant therapeutic potential in a range of
diseases. Through the precise targeting of these proteins, Lexicon
is pioneering the discovery and development of innovative medicines
to treat disease safely and effectively. Lexicon has commercially
launched one of these medicines, INPEFA® (sotagliflozin) in
the United States, and has a pipeline of other promising drug
candidates in discovery and clinical and preclinical development in
neuropathic pain, diabetes and metabolism and other indications.
For additional information, please
visit www.lexpharma.com.
Safe Harbor Statement This press release
contains “forward-looking statements,” including statements
relating to Lexicon’s financial position and long-term outlook on
its business, growth and future operating results, discovery and
development of products, strategic alliances and intellectual
property, as well as other matters that are not historical facts or
information. All forward-looking statements are based on
management’s current assumptions and expectations and involve
risks, uncertainties and other important factors, specifically
including Lexicon’s ability to meet its capital requirements,
successfully commercialize INPEFA in heart failure on the timeline
and/or at the prices currently contemplated or at all, conduct
preclinical and clinical development and obtain necessary
regulatory approvals of sotagliflozin (in other indications),
LX9211 and its other drug candidates on its anticipated timelines,
achieve its operational objectives, obtain patent protection for
its discoveries and establish strategic alliances, as well as
additional factors relating to manufacturing, intellectual property
rights, and the therapeutic or commercial value of its drug
candidates. Any of these risks, uncertainties and other factors may
cause Lexicon’s actual results to be materially different from any
future results expressed or implied by such forward-looking
statements. Information identifying such important factors is
contained under “Risk Factors” in Lexicon’s annual report on Form
10-K for the year ended December 31, 2023 and other subsequent
disclosure documents filed with the Securities and Exchange
Commission. Lexicon undertakes no obligation to update or revise
any such forward-looking statements, whether as a result of new
information, future events or otherwise.
For Investor Inquiries:
Lisa DeFrancescoLexicon Pharmaceuticals,
Inc.lexinvest@lexpharma.com
For Media Inquiries:
Alina CocuzzaLexicon Pharmaceuticals,
Inc.acocuzza@lexpharma.com
Lexicon Pharmaceuticals (NASDAQ:LXRX)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
Lexicon Pharmaceuticals (NASDAQ:LXRX)
Gráfica de Acción Histórica
De May 2023 a May 2024